Lehrer Steven, Rheinstein Peter H
Department of Radiation Oncology, Icahn School of Medicine at Mount Sinai, New York, NY 10029.
Severn Health Solutions, Severna Park, MD 21146, USA.
Int J Funct Nutr. 2021 Jan-Feb;2(1). doi: 10.3892/ijfn.2021.14. Epub 2021 Mar 18.
The FDA has approved only one drug, remdesivir, for the treatment of COVID-19. The FDA has granted an emergency use authorization for the rheumatoid arthritis treatment drug, baricitinib (Olumiant), for the treatment of COVID-19 in some cases. For this reason, investigators have paid considerable attention to the association between commonly used drugs and the outcome of patients with COVID-19. Aspirin and ibuprofen have been reported to reduce the mortality rate. Omeprazole can increase mortality. In addition, some studies have demonstrated that famotidine diminishes mortality, while others have indicated that famotidine leads to a poorer prognosis. The present study used UK Biobank (UKB) data to assess the association of commonly used drugs with COVID-19 mortality. Data processing was performed on Minerva, a Linux mainframe with Centos 7.6. The UK Biobank Data Parser (ukbb_parser) was used, a python-based package that allows easy interfacing with the large UK Biobank dataset. The results revealed that aspirin and omeprazole were associated with an elevated mortality rate. Ibuprofen-related mortality was lower than laxative-related mortality. Aspirin users were also significantly older than other subjects. The association with mortality of cholesterol-lowering medications, blood pressure-lowering medications, hormone replacement and oral contraceptives in 134 female subjects revealed insignificant variability. The association of nutritional supplements in 238 subjects with mortality indicated that variability was insignificant. The lower mortality linked to the supplementation of vitamin D and vitamin B, presumably B complex, has been previously observed. On the whole, the present study demonstrates that although some of the associations described among drugs and COVID-19 are not novel, the utility of a new source, UKB, may prove to be useful in further examining these associations.
美国食品药品监督管理局（FDA）仅批准了一种治疗新冠肺炎的药物——瑞德西韦。FDA已授予类风湿性关节炎治疗药物巴瑞替尼（艾乐明）在某些情况下治疗新冠肺炎的紧急使用授权。因此，研究人员相当关注常用药物与新冠肺炎患者预后之间的关联。据报道，阿司匹林和布洛芬可降低死亡率。奥美拉唑会增加死亡率。此外，一些研究表明法莫替丁可降低死亡率，而另一些研究则表明法莫替丁会导致预后更差。本研究使用英国生物银行（UKB）的数据来评估常用药物与新冠肺炎死亡率之间的关联。数据处理在一台装有Centos 7.6的Linux大型主机Minerva上进行。使用了英国生物银行数据解析器（ukbb_parser），这是一个基于Python的软件包，可轻松连接大型英国生物银行数据集。结果显示，阿司匹林和奥美拉唑与死亡率升高有关。布洛芬相关的死亡率低于泻药相关的死亡率。服用阿司匹林的患者年龄也明显大于其他受试者。对134名女性受试者中降胆固醇药物、降血压药物、激素替代药物和口服避孕药与死亡率的关联分析显示，差异无统计学意义。对238名受试者中营养补充剂与死亡率的关联分析表明，差异无统计学意义。此前已观察到补充维生素D和维生素B（可能是复合维生素B）与较低死亡率相关。总体而言，本研究表明，尽管药物与新冠肺炎之间描述的一些关联并非新发现，但英国生物银行这一新数据源可能有助于进一步研究这些关联。
